Liraglutide Injection, Solution
Product Images NDC 70377-095

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 70377-095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton5s.jpg (Carton5s)

Packaging label for Liraglutide Injection, 18 mg/3 mL (6 mg/mL), supplied as five 3 mL prefilled pens. The product is a subcutaneous injection solution manufactured by Biocon Pharma Inc. The label features storage instructions, dosage increments, and an image of the prefilled pen. It is marked for prescription use and single patient use only, with instructions to refrigerate and protect from light.*

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram showing the amino acid sequence of liraglutide with a C-16 palmitoyl fatty acid attached. The sequence is displayed as circles labeled with amino acid abbreviations connected in a chain, illustrating the peptide composition of liraglutide.*

FDA Label Image

Fig. 5 (Image 02)

A line graph depicting changes in body mass index standard deviation scores (BMI SDS) from baseline over 56 weeks after randomization, comparing liraglutide and placebo groups. Data points include mean values with error bars representing standard error of the mean. The x-axis shows time in weeks, and the y-axis shows BMI SDS change from baseline.*

FDA Label Image

Figure A (Image 08)

An instructional illustration showing hands removing the protective cap from a liraglutide injection pen, depicting the preparation step for subcutaneous injection administration.*

FDA Label Image

Image 02 (Image 09)

Two cumulative frequency graphs showing the change in body weight (%) comparing liraglutide 6 mg/mL injection solution to placebo. The left and right panels both plot cumulative frequency against percent weight change, with liraglutide represented by a solid purple line and placebo by a dotted gray line, illustrating a greater weight change effect with liraglutide compared to placebo.*

FDA Label Image

Image 3 (Image 10)

Line graphs presenting change from baseline (%) in body weight for two studies comparing Liraglutide 6 mg/mL injection versus placebo over 56 weeks. The left graph shows Study 1 with a greater weight reduction for Liraglutide compared to placebo, similarly in Study 2 on the right. Both graphs plot percentage change on the y-axis and weeks on the x-axis, including subject numbers for each group at various time points.*

FDA Label Image

Figure B (Image 11)

An instructional illustration showing a hand holding a prefilled syringe labeled for liraglutide injection. The syringe is marked with dosage measurements from 0.6 mg up to 15, indicating graduated dosing increments for subcutaneous injection.*

FDA Label Image

Image 4 (Image 12)

Line graph showing percentage change in body weight over weeks for patients treated with liraglutide versus placebo. The graph plots weight change from 12 weeks before to 56 weeks after starting a low-calorie diet at week 0. Liraglutide treatment leads to greater weight reduction than placebo throughout the study period. Sample sizes for liraglutide and placebo groups at various weeks are noted below the graph.*

FDA Label Image

Device (Image 47)

Illustration showing parts of a Liraglutide 6 mg/mL injection pen, including the pen cap, pen scale, pen window, dose counter, dose pointer, dose selector, and dose button. Additional components detailed are the outer needle cap, inner needle cap, needle, paper tab, and a close-up of the flow check symbol.*

FDA Label Image

Figure C (Image 48)

An instructional illustration shows a close-up of two hands peeling off a green protective seal from the cap of a small vial or bottle, with a blue arrow indicating the direction to pull the seal away from the vial.*

FDA Label Image

Figure D (Image 49)

Illustration showing a close-up of a hand twisting the cap off a syringe or injection pen. The syringe barrel markings include a visible dose of 0.6 mg. A blue arrow indicates the twisting motion used to remove the cap.*

FDA Label Image

Figure E (Image 50)

Instructional illustration showing a hand removing the cap from a syringe or injection pen, specifically demonstrating part of the preparation process for subcutaneous injection of Liraglutide 6 mg/mL solution. A blue arrow indicates the direction for removing the cap.*

FDA Label Image

Note (Image 51)

Liraglutide 6 mg/mL injection solution for subcutaneous use in a 3 mL glass vial. The label includes the proprietary name Liraglutide, the generic name liraglutide, and is manufactured by Biocon Pharma Inc. The vial is sealed with a metal cap and blue flip-off seal.*

FDA Label Image

Information (Image 52)

Liraglutide 6 mg/mL injection, solution for subcutaneous use, displayed in a vial packaging. The label shows the product name and strength prominently. The product is labeled by Biocon Pharma Inc., with NDC 70377-095.*

FDA Label Image

Figure F (Image 53)

Illustration showing a hand removing the green protective cap from a syringe needle. The syringe barrel is marked with dosage measurements. This is a step in preparing an injection, likely related to Liraglutide 6 mg/mL injection solution for subcutaneous use.*

FDA Label Image

Flow Check Symbol (Image 54)

Liraglutide 6 mg/mL injection, solution in a 3 mL prefilled pen cartridge package. The packaging features the Biocon Pharma Inc. logo and includes usage instructions with text and numbered illustrations. It is intended for subcutaneous administration.*

FDA Label Image

Figure G (Image 55)

An instructional diagram showing a close-up of the Liraglutide 6 mg/mL injection device held between two hands. The image highlights the 'Flow check symbol selected' on the dose selector window, indicating how to confirm the flow for administration.*

FDA Label Image

Note (Image 56)

Liraglutide 6 mg/mL injection, solution in a 3 mL single-dose prefilled pen syringe. The label shows the product name Liraglutide, active ingredient liraglutide, and the strength. The injection is intended for subcutaneous use. Labeler information is Biocon Pharma Inc.*

FDA Label Image

Information (Image 57)

Liraglutide 6 mg/mL injection solution for subcutaneous use in a vial packaging. The label includes the proprietary name Liraglutide, generic name liraglutide, strength, and manufacturer Biocon Pharma Inc. The product NDC 70377-095 is also visible.*

FDA Label Image

Figure H (Image 58)

An instructional illustration showing a hand holding a Liraglutide 6 mg/mL injection pen, demonstrating the upward removal of the cap from the pen needle. The image highlights how to properly grip the pen and pull off the cover, with a close-up inset of the needle cap.*

FDA Label Image

Note (Image 59)

Liraglutide 6 mg/mL injection solution in a vial, labeled for subcutaneous use. The vial is clear with a white label displaying the product name, strength, and manufacturer, Biocon Pharma Inc. The packaging is consistent with a prescription drug intended for injection.*

FDA Label Image

Information (Image 60)

FDA Label Image

Figure I (Image 61)

An instructional illustration showing a person holding a Liraglutide injection pen and adjusting the dose selection window to 0.6 mg. The image emphasizes the visual display of the selected dose on the pen's dial, with arrows indicating dose adjustment and a labeled example of 0.6 mg selected.*

FDA Label Image

Information (Image 62)

FDA Label Image

Figure J (Image 63)

Illustration showing a syringe with measurement markings indicating an approximate 3 mg dose left in the syringe. Includes annotation labeled 'Example Approx. 3 mg left.' The syringe is intended for subcutaneous injection.*

FDA Label Image

Information (Image 64)

FDA Label Image

Note (Image 65)

Liraglutide 6 mg/mL injection solution for subcutaneous use in a multi-dose vial. The label includes the product name, strength, administration route, and the Biocon Pharma Inc. logo as the manufacturer. The vial label contains dosage and storage information as visible.*

FDA Label Image

Figure K (Image 66)

An instructional illustration showing hands adjusting the dose counter on a liraglutide injection pen. The example dose displayed on the dial is 2.4 mg. It demonstrates how to read the dose counter which indicates the remaining dose left in the pen.*

FDA Label Image

Figure L (Image 67)

An illustration showing a hand holding a liraglutide injection pen for subcutaneous use. The pen is held vertically with a dosage scale visible, marked from 0.6 mg and upwards. A downward arrow indicates the direction of injection into the skin.*

FDA Label Image

Figure M (Image 68)

An instructional illustration showing a hand holding a liraglutide injection device, with an arrow pointing downward. The device display shows a dosage of 0 mg, indicating readiness to set a dose for subcutaneous injection.*

FDA Label Image

Figure N (Image 69)

An instructional illustration showing a hand holding a liraglutide injection pen. The image includes a step labeled 'N' with a speech bubble indicating to count slowly from 1 to 6, suggesting a timing or injection technique for the subcutaneous liraglutide 6 mg/mL solution by Biocon Pharma Inc.*

FDA Label Image

Note (Image 70)

Liraglutide 6 mg/mL injection solution label for subcutaneous use by Biocon Pharma Inc. The label includes branding, product strength, dosage form, and route of administration. It displays regulatory and manufacturing information typical for human prescription drug packaging.*

FDA Label Image

Information (Image 71)

Liraglutide 6 mg/mL injection, solution in a subcutaneous dosage form. The label shows the product name Liraglutide, the active ingredient liraglutide, strength 6 mg/mL, and indicates it is manufactured by Biocon Pharma Inc. The label also displays the product NDC 70377-095.*

FDA Label Image

Figure O (Image 72)

An instructional illustration showing a syringe with measurement markings from 0.6 mg to 15 units, positioned vertically with the needle pointing downward. A large blue arrow points upward beside the syringe, indicating an action or direction related to the syringe's use.*

FDA Label Image

Figure P (Image 73)

An instructional illustration showing a close-up of a hand removing a protective cap from the needle of a syringe. The syringe is marked with dosage measurements, focusing on the 6 mg level. A blue 'P' icon and arrow indicate the direction of cap removal.*

FDA Label Image

Figure Q (Image 74)

An instructional illustration showing a needle cap being removed or attached to a yellow container lid, indicated by a downward blue arrow. The image is likely part of usage or disposal instructions for a subcutaneous injection product.*

FDA Label Image

Figure R (Image 75)

An instructional illustration showing a hand holding a prefilled injectable pen. The other hand is turning the dosage selector on the pen, highlighting the dose markings on the pen barrel. The illustration demonstrates setting or adjusting the dose for a subcutaneous injection device.*

FDA Label Image

Information (Image 76)

FDA Label Image

Note (Image 77)

Liraglutide 6 mg/mL injection solution vial label. The label shows the proprietary name Liraglutide, active ingredient liraglutide, dosage form injection solution for subcutaneous use, and strength 6 mg/mL. It is labeled by Biocon Pharma Inc. and includes the NDC code 70377-095. The vial is clear with a purple cap.*

FDA Label Image

Information (Image 78)

Liraglutide 6 mg/mL injection, solution for subcutaneous use. The label displays the product name Liraglutide, the concentration of 6 mg/mL, and indicates it is a human prescription drug. The labeler is Biocon Pharma Inc. The packaging is designed for an injectable solution.*

FDA Label Image

Figure S (Image 79)

An illustration showing the assembly of a syringe cap with the syringe tip, featuring directional arrows indicating how to attach the cap securely onto the syringe. The image background is light blue with a white square labeled "S" in the top left corner.*

FDA Label Image

Note (Image 80)

Liraglutide 6 mg/mL injection, solution for subcutaneous use, labeled by Biocon Pharma Inc. The packaging includes a box and a single injection pen device. The box features the product name and strength prominently, with additional text and branding. The pen is predominantly white with a yellow cap and appears to be a single-dose or multi-dose injectable device.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.